“We believe that the most rapid and impactful advances in cancer treatment have and will come from working together. “
Christoph Korpus, PhD, MBA, Chief Executive Officer
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical development, process development and manufacturing.
Investors & Media
Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Contact us by filling in the form below or send an email to BD@Byondis.com
Personal data contained in this form is intended for the sole use of Byondis.
We will use this data to respond to your question or obtain additional information from you as needed.
Please see the Byondis Privacy and cookie statement.
Our Science
Our novel drug development platform is based on multiple, seamlessly integrated, proprietary technologies with enhanced tumor targeting selectivity, optimized linkers, broad diversity of targets, payloads & MoA.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
